Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Anton Schattenberg"'
Autor:
Gösta Gahrton, Simona Iacobelli, Giuseppe Bandini, Bo Björkstrand, Paolo Corradini, Charles Crawley, Ute Hegenbart, Gareth Morgan, Nicolaus Kröger, Anton Schattenberg, Stefan O. Schönland, Leo F. Verdonck, Lisa Volin, Theo de Witte, Dietger Niederwieser, the Myeloma Subcommittee of the EBMT
Publikováno v:
Haematologica, Vol 92, Iss 11 (2007)
Background and Objectives Peripheral blood stem cells (PBSC) following reduced intensity conditioning (RIC) are being increasingly used for allogeneic transplantation in multiple myeloma. The purpose of this study was to compare outcome of patients t
Externí odkaz:
https://doaj.org/article/cbf33d9ebd6a4ede8492bf44c5405b1f
Autor:
Gérard Socié, Jordi Esteve, Christoph Schmid, Jan J. Cornelissen, Tomasz Czerw, Arnaud Pigneux, Ibrahim Yakoub-Agha, Sebastian Giebel, Vladimir Koza, Hélène Labussière-Wallet, Nigel H. Russell, Depei Wu, Avichai Shimoni, Mohamad Mohty, Patrice Chevallier, Arnon Nagler, Myriam Labopin, Zinaida Peric, Liisa Volin, Anton Schattenberg, Rainer Schwerdtfeger, Robin Foà, Johan Maertens
Publikováno v:
Leukemia, 35(8), 2232-2242. Nature Publishing Group
Adult B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with t(4;11)(q21;q23);KMT2A/AFF1 is a poor-prognosis entity. This registry-based study was aimed to analyze outcome of patients with t(4;11) BCP-ALL treated with allogeneic hematopoietic s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26b0fe5768301fe3a7fe99bc0763e293
https://pubmed.ncbi.nlm.nih.gov/33542481
https://pubmed.ncbi.nlm.nih.gov/33542481
Autor:
Hans-Jochem Kolb, Johanna Tischer, Thomas Schroeder, Manuela Badoglio, Wilfried Schroyens, Denis Guyotat, Yves Beguin, Nina Salooja, Nicole Engel, Alicia Rovó, Gérard Socié, Myriam Labopin, Per Ljungman, Rafael F. Duarte, Grzegorz W. Basak, Arnon Nagler, Anton Schattenberg, André Tichelli
Publikováno v:
Leukemia
Donor cell leukaemia (DCL) is a rare complication of allogeneic haematopoietic cell transplantation (HCT). We have investigated the prevalence and outcome of donor cell haematology malignancies within centres registered with the European Society of B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34ff27255b779ca76ffed014849c9381
https://doi.org/10.1038/s41375-018-0218-6
https://doi.org/10.1038/s41375-018-0218-6
Autor:
Wendy Deenik, Willem M. Smit, Jeroen Janssen, Noortje Thielen, Gert J. Ossenkoppele, Pieter Sonneveld, Gregor Verhoef, Peter J. M. Valk, J.H. Frederik Falkenburg, Harm Sinnige, Rianne A. H. M. Ammerlaan, Anton Schattenberg, Isabel W. T. Chu, M. Schipperus, Bronno van der Holt, Jan J. Cornelissen, Rien van Marwijk Kooy, Marie José Kersten
Publikováno v:
Annals of Hematology, 92, 8, pp. 1049-56
Thielen, N, van der Holt, B, Verhoef, G E G, Ammerlaan, R A H M, Sonneveld, P, Janssen, J J W M, Deenik, W, Falkenburg, J H F, Kersten, M J, Sinnige, H A M, Schipperus, M, Schattenberg, A, Kooy, R V, Smit, W M, Chu, I W T, Valk, P J M, Ossenkoppele, G J & Cornelissen, J J 2013, ' High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group ', Annals of Hematology, vol. 92, no. 8, pp. 1049-1056 . https://doi.org/10.1007/s00277-013-1730-4
Annals of hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056
Annals of Hematology, 92, 1049-56
Thielen, N, van der Holt, B, Verhoef, G E G, Ammerlaan, R A H M, Sonneveld, P, Janssen, J J W M, Deenik, W, Falkenburg, J H F, Kersten, M J, Sinnige, H A M, Schipperus, M, Schattenberg, A, Kooy, R V, Smit, W M, Chu, I W T, Valk, P J M, Ossenkoppele, G J & Cornelissen, J J 2013, ' High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group ', Annals of Hematology, vol. 92, no. 8, pp. 1049-1056 . https://doi.org/10.1007/s00277-013-1730-4
Annals of hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056
Annals of Hematology, 92, 1049-56
Item does not contain fulltext Despite the revolutionary change in the prognosis of chronic myeloid leukemia (CML) patients with the introduction of imatinib, patients with resistant disease still pose a considerable problem. In this multicenter, ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fb5649d7382925fb68cdb50d11ac25d
https://doi.org/10.1007/s00277-013-1730-4
https://doi.org/10.1007/s00277-013-1730-4
Autor:
Anja van Biezen, Alois Gratwohl, Catherine Cordonnier, Nicolaus Kröger, Dominique Bron, Carlos Richard, Hans-Jochem Kolb, Jane F. Apperley, Tapani Ruutu, William Arcese, Gösta Gahrton, Dietger Niederwieser, Anton Schattenberg, Augustin Ferrant, Renate Arnold, Francesco Frassoni, Simona Iacobelli, Natalia Bootsman, Eduardo Olavarria, F. E. Zwaan, Peter B. Ernst, Norbert Schmitz, Marrow Transplantation Ebmt, Helen Baldomero, Hartmut Link, Antonio Torres-Gomez
Publikováno v:
Annals of Hematology, 95, 967-72
Annals of Hematology, 95, 6, pp. 967-72
Annals of Hematology, 95(6), 967-972
Annals of Hematology, 95, 6, pp. 967-72
Annals of Hematology, 95(6), 967-972
Item does not contain fulltext In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7909b338469581dcad8cb6ce58cfe41a
http://hdl.handle.net/2066/171530
http://hdl.handle.net/2066/171530
Autor:
Lucia E. Duinhouwer, Leo F. Verdonck, Wil A. Allebes, E. Meijer, Eefke Petersen, Anton Schattenberg, M. Groenendijk-Sijnke, Roelof Willemze, Machteld Oudshoorn, T. Lodewyck, Bob Löwenberg, Jan J. Cornelissen, B. van der Holt, P.A. von dem Borne, Eric Spierings
Publikováno v:
Leukemia, 25, 10, pp. 1548-54
Leukemia, 25(10), 1548. Nature Publishing Group
Leukemia, 25, 1548-54
Leukemia, 25(10), 1548-1554. Nature Publishing Group
Leukemia, 25(10), 1548-1554
Leukemia, 25(10), 1548. Nature Publishing Group
Leukemia, 25, 1548-54
Leukemia, 25(10), 1548-1554. Nature Publishing Group
Leukemia, 25(10), 1548-1554
Many parameters predict for outcome after unrelated donor (URD) allogeneic hematopoietic stem cell transplantation (alloSCT). High-resolution HLA-matching significantly impacts outcome and also the European Group of Blood and Marrow Transplantation (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f19db2645782f91ef60aa93c975ae59
https://hdl.handle.net/1765/26370
https://hdl.handle.net/1765/26370
Autor:
Guido Kobbe, Jan J. Cornelissen, Nigell Russell, Jean-Paul Vernant, Carme Canals, Silvia Montoto, Yves Beguin, Ghulam J. Mufti, Irit Avivi, Anton Schattenberg, Renato Fanin, Kirsty Thomson, Juergen Finke, J Maertens, Gérard Socié, Hervé Tilly, Haifa Kathrin Al-Ali, Anna Sureda, Leo F. Verdonck
Publikováno v:
British Journal of Haematology. 147:719-728
Matched unrelated donor stem cell transplantation (MUD-SCT) provides the only curative option for patients with follicular lymphoma (FL) who fail conventional therapies and do not have a sibling donor. The purpose of this study was to analyse the out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e2753844d4c546450cbac751a399ceb
https://doi.org/10.1111/j.1365-2141.2009.07905.x
https://doi.org/10.1111/j.1365-2141.2009.07905.x
Autor:
Henk J. Tijssen, Nicolaas Schaap, Anton Schattenberg, Bram van Cranenbroek, Irma Joosten, Arnold van der Meer
Publikováno v:
Molecular Immunology, 45, 13, pp. 3631-8
Molecular Immunology, 45, 3631-8
Molecular Immunology, 45, 3631-8
Contains fulltext : 69575.pdf (Publisher’s version ) (Closed access) BACKGROUND: Alloreactive NK cells play a role in tumor eradication after allogeneic HLA mismatched stem cell transplantation (SCT). The effect of NK alloreactivity in HLA identica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ee3493f7916a1e9cf253c6f7d6cc11
https://doi.org/10.1016/j.molimm.2008.04.016
https://doi.org/10.1016/j.molimm.2008.04.016
Autor:
H. Berna Beverloo, Jan J. Cornelissen, Anton Schattenberg, Hanneke C. Kluin-Nelemans, Jeroen Janssen, Pierre W. Wijermans, Gregor Verhoef, Peter J. M. Valk, Augustin Ferrant, Marie José Kersten, Bob Löwenberg, Pieter Sonneveld, Bronno van der Holt, Willem M. Smit, Gert J. Ossenkoppele, S. Wittebol, Marinus van Marwijk Kooy, Petra H. M. Westveer, Roelof Willemze, Wendy Deenik, Leo F. Verdonck
Publikováno v:
Blood, 111(5), 2581-2588. American Society of Hematology
Blood, 111(5), 2581-2588. AMER SOC HEMATOLOGY
Blood, 111, 5, pp. 2581-2588
Deenik, W, van der Holt, B, Verhoef, GE, Smit, W M, Kersten, M J, Kluin-Nelemans, H C, Verdonck, L F, Ferrant, A, Schattenberg, A V, Janssen, J J W M, Sonneveld, P, van Marwijk, K M, Wittebol, S, Willemze, R, Wijermans, P W, Westveer, PH, Beverloo, HB, van der Valk, P, Lowenberg, B, Ossenkoppele, G J & Cornelissen, J J 2008, ' Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia ', Blood, vol. 111, no. 5, pp. 2581-2588 . https://doi.org/10.1182/blood-2007-08-107482
Blood, 111, 2581-2588
Blood, 111(5), 2581-2588. AMER SOC HEMATOLOGY
Blood, 111, 5, pp. 2581-2588
Deenik, W, van der Holt, B, Verhoef, GE, Smit, W M, Kersten, M J, Kluin-Nelemans, H C, Verdonck, L F, Ferrant, A, Schattenberg, A V, Janssen, J J W M, Sonneveld, P, van Marwijk, K M, Wittebol, S, Willemze, R, Wijermans, P W, Westveer, PH, Beverloo, HB, van der Valk, P, Lowenberg, B, Ossenkoppele, G J & Cornelissen, J J 2008, ' Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia ', Blood, vol. 111, no. 5, pp. 2581-2588 . https://doi.org/10.1182/blood-2007-08-107482
Blood, 111, 2581-2588
Contains fulltext : 70504schattenberg.pdf (Publisher’s version ) (Closed access) The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase chronic myelo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f131f5681d74cee672cbe2409de65f3
https://doi.org/10.1182/blood-2007-08-107482
https://doi.org/10.1182/blood-2007-08-107482
Autor:
J.M. van Laar, A.P.J. van Dijk, Dominique Farge, F.H.J. van den Hoogen, P.L.C.M. van Riel, P Roblot, Eliane Gluckman, Jérôme Larghero, Frank Preijers, J J Bax, Anton Schattenberg, Zora Marjanovic, Willem E. Fibbe, Sarah Zohar, Madelon C. Vonk
Publikováno v:
Annals of the Rheumatic Diseases, 67, 98-104
Annals of the Rheumatic Diseases, 67, 1, pp. 98-104
Annals of the Rheumatic Diseases, 67, 1, pp. 98-104
Contains fulltext : 69053schattenberg.pdf (Publisher’s version ) (Closed access) OBJECTIVE: Systemic sclerosis (SSc) is a generalised autoimmune disease, causing morbidity and a reduced life expectancy, especially in patients with rapidly progressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dc365e8bdc12900cc397d015a403ea1
https://doi.org/10.1136/ard.2007.071464
https://doi.org/10.1136/ard.2007.071464